Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bisphosphonates Might Get Limits On Treatment Duration Following Label Change

This article was originally published in The Pink Sheet Daily

Executive Summary

Accumulating data on femur fractures lead FDA to consider telling physicians to take patients off the drug at least temporarily when bone mineral density targets are reached.

You may also be interested in...



Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee

FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."

Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee

FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."

Genentech Fields Overstated Claim For Boniva, DDMAC Says

The ad for the osteoporosis drug - featuring actress Sally Field and running in Parade magazine - was improperly based on a post-hoc responder analysis, DDMAC says.

Related Content

Topics

UsernamePublicRestriction

Register

PS071299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel